Skip to main content

Exhalation Delivery System With Fluticasone Effective for Rhinosinusitis

Medically reviewed by Judith Stewart, BPharm. Last updated on Jan 26, 2024.

By Elana Gotkine HealthDay Reporter

FRIDAY, Jan. 26, 2024 -- For patients with chronic rhinosinusitis (CRS), an exhalation delivery system that delivers fluticasone (EDS-FLU) to sinonasal areas above the inferior turbinate is efficacious, irrespective of nasal polyps, according to a study published online Jan. 18 in the Journal of Allergy and Clinical Immunology: In Practice.

James N. Palmer, M.D., from the University of Pennsylvania Perelman School of Medicine in Philadelphia, and colleagues examined EDS-FLU efficacy for CRS in two randomized, EDS-placebo-controlled trials in adults with CRS irrespective of polyps (ReOpen1; 332 patients) or exclusively without polyps (ReOpen2; 223 patients). For 24 weeks, patients received EDS-FLU one or two sprays/nostril or EDS-placebo twice daily.

The researchers found that the composite symptom score least-squares mean change for EDS-FLU one or two sprays/nostril versus EDS-placebo was −1.58 and −1.60 versus −0.62 in ReOpen1, and −1.54 and −1.74 versus −0.81 in ReOpen2. Sinus opacification least-squares mean change for one or two sprays/nostril of EDS-FLU versus EDS-placebo was −5.58 and −6.20 versus −1.60 in ReOpen1 and −7.00 and −5.14 versus +1.19 in ReOpen2. Compared with EDS-placebo, acute disease exacerbations were reduced by 56 to 66 percent with EDS-FLU. For patients using standard-delivery nasal steroid products just before entering the study, there were significant symptom reductions of a similar magnitude observed. Similar adverse events were seen to those with standard-delivery intranasal steroids.

"These findings provide strong evidence for an effective, noninvasive treatment option for people who continue to experience symptoms after over-the-counter medications have failed," Palmer said in a statement.

Several authors disclosed ties to pharmaceutical companies, including OptiNose US, which funded the study.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Read this next

Neoadjuvant Chemo Boosts Structure Preservation Rates in Nasal, Sinus Cancer

WEDNESDAY, Sept. 18, 2024 -- Neoadjuvant platinum-based chemotherapy improves structure preservation (SP) for patients with T3, T4a, and selected T4b resectable nasal and...

Bidirectional Link Seen for Psychiatric Disorders With Chronic Rhinosinusitis

MONDAY, Sept. 16, 2024 -- There is a bidirectional association for anxiety and depression with chronic rhinosinusitis (CRS), according to a study published online Sept. 12 in JAMA...

Nasal Sprays, Behavioral Intervention Aid in Treatment of Respiratory Illness

TUESDAY, July 30, 2024 -- Use of nasal sprays and a behavioral intervention promoting physical activity and stress management can reduce antibiotic use for respiratory illness...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.